Literature DB >> 23561999

Turning a blind eye to deferasirox's toxicity?

G J Kontoghiorghes.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23561999     DOI： 10.1016/S0140-6736(13)60799-0

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  6 in total

1.  New developments and controversies in iron metabolism and iron chelation therapy.

Authors:  Christina N Kontoghiorghe; George J Kontoghiorghes
Journal:  World J Methodol       Date:  2016-03-26

Review 2.  World health dilemmas: Orphan and rare diseases, orphan drugs and orphan patients.

Authors:  Christina N Kontoghiorghe; Nicholas Andreou; Katerina Constantinou; George J Kontoghiorghes
Journal:  World J Methodol       Date:  2014-09-26

Review 3.  Deferasirox nephrotoxicity-the knowns and unknowns.

Authors:  Juan Daniel Díaz-García; Angel Gallegos-Villalobos; Liliana Gonzalez-Espinoza; Maria D Sanchez-Niño; Jesus Villarrubia; Alberto Ortiz
Journal:  Nat Rev Nephrol       Date:  2014-07-22       Impact factor: 28.314

4.  Reversible retinopathy associated with oral deferasirox therapy.

Authors:  Harpreet S Walia; Jiong Yan
Journal:  BMJ Case Rep       Date:  2013-07-17

Review 5.  Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes.

Authors:  Christina N Kontoghiorghe; George J Kontoghiorghes
Journal:  Drug Des Devel Ther       Date:  2016-01-29       Impact factor: 4.162

6.  Deferasirox-induced iron depletion promotes BclxL downregulation and death of proximal tubular cells.

Authors:  Diego Martin-Sanchez; Angel Gallegos-Villalobos; Miguel Fontecha-Barriuso; Susana Carrasco; Maria Dolores Sanchez-Niño; Francisco J Lopez-Hernandez; Marta Ruiz-Ortega; Jesus Egido; Alberto Ortiz; Ana Belén Sanz
Journal:  Sci Rep       Date:  2017-01-31       Impact factor: 4.379
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.